产品说明书

Vecabrutinib

Print
Chemical Structure| 1510829-06-7 同义名 : SNS-062
CAS号 : 1510829-06-7
货号 : A586120
分子式 : C22H24ClF4N7O2
纯度 : 99%+
分子量 : 529.918
MDL号 : MFCD31692359
存储条件：

粉末 Keep in dark place,Sealed in dry,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 120 mg/mL(226.45 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 Bruton’s tyrosine kinase (BTK), a member of the Tec family of tyrosine kinases and expressed in B cells, macrophages, and monocytes but not in T cells, plays a crucial role in signaling through the B cell receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively [1]. Vecabrutinib is a potent, noncovalent BTK and ITK (interleukin-2-inducible kinase) inhibitor, with Kd of 0.3 nM and 2.2 nM, respectively. It inhibits WT and C481S BTK with IC50s of 2.9 nM and 4.4 nM, respectively. Vecabrutinib decreases viability of primary CLL cells in the presence of HS5 stromal protection by 5.5%. Vecabrutinib has good oral bioavailability in rat and dog (%F ≥ 40%) and a terminal half-life of 5 to 6 hours and is well tolerated with continuous drug levels.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03037645 Chronic Lymphocytic Leukemia ... 展开 >> Small Lymphocytic Lymphoma Lymphoplasmacytoid Lymphoma Mantle-Cell Lymphoma Waldenstrom Macroglobulinemia Diffuse Large B Cell Lymphoma Follicular Lymphoma 收起 << Phase 1 Phase 2 Recruiting June 30, 2021 United States, California ... 展开 >> University of California Irvine Medical Center Recruiting Orange, California, United States, 92868-3201 Contact: General Contact    877-827-8839    ucstudy@uci.edu    UC San Diego Moores Cancer Center Recruiting San Diego, California, United States, 92093 Contact: Barbara Ivers    858-822-6281    bivers@ucsd.edu    United States, Florida Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Natalie Miller    813-745-2591    Natalie.Miller@moffitt.org    United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Conner Shaughnessy    617-582-8437    Conner_Shaughnessy@dfci.harvard.edu    United States, New York Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Isaac Deonarine    646-888-1319    deonarii@mskcc.org    Weill Cornell Medicine Recruiting New York, New York, United States, 10065 Contact: Jessica Harper    646-962-9414    jah2070@med.cornell.edu    United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Chongjuan Wei    713-792-3530    cwei@mdanderson.org    United States, Washington Swedish Cancer Institute Recruiting Seattle, Washington, United States, 98104 Contact: Ngan Trinh    206-215-2363    Ngan.Trinh@Swedish.org 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.89mL

0.38mL

0.19mL

9.44mL

1.89mL

0.94mL

18.87mL

3.77mL

1.89mL
参考文献

[1]Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655. doi: 10.1021/acs.jmedchem.9b00794. Epub 2019 Aug 15. PMID: 31368705.